Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Next Previous
Trial Profile

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Celecoxib (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Estradiol (Primary) ; Metformin (Primary) ; Zoledronic acid (Primary) ; Antiandrogens; Apalutamide; Degarelix; Goserelin; Leuprorelin; Prednisolone; Prednisone; Triptorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAMPEDE

    • Most Recent Events

    • 01 Jan 2024 Results from NCT00303784 and NCT00268476 assessing androgen suppression, quality of life and bone health indices and cardiovascular events , published in the Clinical Oncology
    • 24 Oct 2023 Results (n=1791) assessing long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer with follow-up to Mar 2021 for patients randomised 1:1 in England between arms A (standard of care [SOC]) and H (SOC+RT) presented at the 48th European Society for Medical Oncology Congress
    • 24 Oct 2023 Results comparing treatment regimens androgen deprivation therapy or docetaxel in the control or research arms in mHSPC were utilized from 13 trials which includes (NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646) studies, presented at the 48th European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top